EA202092264A1 - Лечение и профилактика амилоидоза - Google Patents

Лечение и профилактика амилоидоза

Info

Publication number
EA202092264A1
EA202092264A1 EA202092264A EA202092264A EA202092264A1 EA 202092264 A1 EA202092264 A1 EA 202092264A1 EA 202092264 A EA202092264 A EA 202092264A EA 202092264 A EA202092264 A EA 202092264A EA 202092264 A1 EA202092264 A1 EA 202092264A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amyloidosis
prevention
treatment
antibody
methods
Prior art date
Application number
EA202092264A
Other languages
English (en)
Inventor
Тарлочан Ниджар
Филип Дж. Долан III
Робин Барбур
Original Assignee
Протена Байосайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Протена Байосайенсиз Лимитед filed Critical Протена Байосайенсиз Лимитед
Publication of EA202092264A1 publication Critical patent/EA202092264A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Способы лечения амилоидоза AL, связанного с отложением неправильно свернутых белков легкой цепи иммуноглобулина, и соответствующие способы применения, связанные с антителом, таким как антитело 2A4, или фармацевтическим составом, содержащим антитело.
EA202092264A 2018-03-23 2019-03-22 Лечение и профилактика амилоидоза EA202092264A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647341P 2018-03-23 2018-03-23
PCT/US2019/023528 WO2019183448A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Publications (1)

Publication Number Publication Date
EA202092264A1 true EA202092264A1 (ru) 2020-12-03

Family

ID=66041747

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092264A EA202092264A1 (ru) 2018-03-23 2019-03-22 Лечение и профилактика амилоидоза

Country Status (12)

Country Link
US (1) US20210017278A1 (ru)
EP (1) EP3768311A1 (ru)
JP (1) JP7217287B2 (ru)
KR (1) KR20200143400A (ru)
CN (1) CN112040983A (ru)
AU (2) AU2019240413A1 (ru)
BR (1) BR112020019172A2 (ru)
CA (1) CA3095100A1 (ru)
EA (1) EA202092264A1 (ru)
MX (1) MX2020009920A (ru)
SG (1) SG11202009295YA (ru)
WO (1) WO2019183448A1 (ru)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2237803B1 (en) * 2007-12-28 2015-07-01 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
JP2019519584A (ja) * 2016-06-30 2019-07-11 プロシーナ バイオサイエンシーズ リミテッド アミロイドーシスを処置するための組成物

Also Published As

Publication number Publication date
KR20200143400A (ko) 2020-12-23
US20210017278A1 (en) 2021-01-21
JP7217287B2 (ja) 2023-02-02
BR112020019172A2 (pt) 2021-01-26
AU2023202109A1 (en) 2023-05-18
JP2021518393A (ja) 2021-08-02
CA3095100A1 (en) 2019-09-26
MX2020009920A (es) 2020-12-10
EP3768311A1 (en) 2021-01-27
SG11202009295YA (en) 2020-10-29
WO2019183448A1 (en) 2019-09-26
CN112040983A (zh) 2020-12-04
AU2019240413A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
PE20190737A1 (es) Anticuerpos anti-cd27
EA201992091A1 (ru) Анти-c5 антитела и их применение
BR112016015867A2 (pt) anticorpos de elevada afinidade e resistentes à agregação com base nas regiões variáveis vl e no derivado vhh
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
EA201991726A1 (ru) Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
EA202092420A1 (ru) Антитело против pd-l1 и его применение
EA201890340A1 (ru) Моноклональное антитело-ингибитор фактора xiia
BR112017022073A2 (pt) método para purificação de proteína
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
CY1126054T1 (el) Πεπτιδια για θεραπεια και αποτροπη διαβητη και συναφων διαταραχων
PE20190633A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
ZA202205288B (en) Humanized antibody and method for using the same
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation